Without brain data, we won’t improve outcomes for patients who have neurological diseases
New technologies for quantifying behavioral information and tracking neurological patterns have the potential to change treatment—but we must connect the data.
Vying to best bigger rivals in Parkinson’s, Neuron23 nabs $100M to reach clinic
Neuron23 is developing drugs that treat neurological conditions by penetrating the blood-brain barrier to reach disease targets in the central nervous system. The biotech's lead program is a Parkinson’s disease drug candidate with features that could distinguish it from rival compounds that are aiming for the same target.
presented by
Your Guide to the Best Vein Clinics in Orlando
Your varicose or spider veins may indicate an underlying problem, so finding the right vein specialist is crucial. Discover the best vein clinics in Orlando.
Cash woes at neuro biotech Yumanity lead to 60% staff cut and search for a buyer
Yumanity’s corporate restructuring means the biotech is now exploring “strategic alternatives” that could include a sale of the company or its assets. The biotech’s lead drug candidate is an experimental Parkinson’s disease drug currently in Phase 1 testing.
Sanofi shores up neuro pipeline with deal for brain-penetrating Parkinson’s drug
Sanofi is the latest company to strike a deal for a Parkinson’s disease drug candidate that targets the protein alpha synuclein. The asset from ABL Bio is a bispecific antibody designed to penetrate the blood-brain barrier.
Novartis boosts neuro pipeline through alliance on UCB Parkinson’s drugs
Novartis is paying UCB $150 million up front to share in the development of two clinical-stage Parkinson’s disease drugs that offer new approaches to treating the disease. Depending on the progress of those drugs, UCB could earn up to $1.5 billion in milestone payments.
At HLTH, a case for empowering patients in research
At HLTH, leaders of the Michael J. Fox Foundation shared the importance of including patient voices in research, and how engaging patients has led to important findings in Parkinson’s research.
Solving Healthcare’s Provider Data Problem Starts with Interoperability
Break down the silos. Take control of your provider data.
Neuro startup Vanqua Bio emerges with $85M and a first focus on Parkinson’s
Vanqua Bio aims to treat rare form of Parkinson’s disease by boosting activity of an enzyme that is deficient in patients who have a particular genetic mutation. With $85 million in Series B financing, the biotech startup, which is based on Northwestern University research, aims to reach human testing within two years.
Mayo Clinic, Google develop AI algorithm to enhance electrical brain stimulation
The algorithm maps interactions between different areas of the brain, which can help guide the placement of electrodes for stimulating devices to treat brain diseases, like epilepsy, and movement disorders.
AC Immune picks up Phase 2-ready drug for Parkinson’s in $58M deal with Affiris
AC Immune is bolstering the Parkinson’s disease portion of its drug pipeline with a deal to acquire a therapeutic vaccine that Affiris is developing for the disorder. Switzerland-based AC Immune plans to advance its new asset to Phase 2 testing.
GSK adds neuro prospects, paying $700M to share R&D of Alector’s two lead drugs
GlaxoSmithKline is paying Alector $700 million up front to share in the development of the biotech’s two lead drugs, which offer potentially broad application in treating neurological disorders. Alector’s approach addresses the role immune cell dysfunction plays in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.
presented by
Navina’s AI Copilot Eases the Value-Based Burden, Study Shows
A new independent study from Phyx Primary Care’s Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices.
FDA grants breakthrough designation to a light device for the treatment of Parkinson’s
PhotoPharmics has raised $11 million and aims to raise another $10 million to help in the development and commercialization of its specialized light therapy device to treat Parkinson's Disease.
Biogen teams up with Sangamo in gene therapy deal worth up to $2.7B
Biogen, which Sangamo selected from among several companies in a competitive process, will pay the biotech company $350 million upfront, along with up to $2.37 billion in milestone payments.
Insightec wants to usher in a new era of incisionless surgery
The Israeli company's technology uses the power of focused ultrasound guided by MR imaging to target conditions like essential tremor, Parkinson's disease and neuropathic pain.
Prevail Therapeutics raises $50M for gene therapy in Parkinson’s, other neurodegenerative disorders
The company hopes the funding will move it toward the clinic. Active clinical programs of gene therapies in Parkinson's include efforts by Voyager Therapeutics and a university in Japan.
Bain invests $350M in new company Cerevel to develop Pfizer’s neuroscience pipeline
Cerevel will take on several clinical and preclinical candidates from Pfizer, which divested from neuroscience this year and will take a 25 percent stake in the new company.